| Code | CSB-RA004888MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to FMC63, targeting CD19, a B-cell specific surface glycoprotein that plays a critical role in B-cell development, activation, and proliferation. CD19 is expressed throughout B-cell differentiation from pre-B cells to mature B lymphocytes but is lost upon differentiation into plasma cells. As a co-receptor in the B-cell receptor complex, CD19 lowers the threshold for antigen-mediated B-cell activation and enhances signal transduction. CD19 is widely expressed in B-cell malignancies including B-cell acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia, making it an important therapeutic target and biomarker.
FMC63 is a well-established murine monoclonal antibody that has served as the foundation for FDA-approved CAR-T cell therapies targeting CD19-positive malignancies. This biosimilar provides researchers with a reliable tool for investigating CD19 biology, B-cell signaling pathways, and immunotherapeutic mechanisms. It is suitable for various research applications exploring B-cell function, lymphoid malignancies, and antibody-based therapeutic development.
There are currently no reviews for this product.